Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged undisclosed information regarding the company's regulatory submissions and business prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that between March 7, 2024, and May 23, 2025, Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The lawsuit asserts that the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Participation Information - Investors who suffered losses on their Savara investments are encouraged to participate in the lawsuit before the lead plaintiff deadline of November 7, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps that could endanger patients and lead to significant financial losses for investors [1][2]. Company Summary - On August 7, 2025, Tandem disclosed a malfunction in some of its insulin pumps that could lead to a discontinuation of insulin delivery, potentially resulting in hyperglycemia and requiring hospitalization [2]. - The company notified affected customers between July 22 and 24, 2025, about the issue [2]. - Following this announcement, Tandem's stock price dropped by $2.87, or 19.9%, closing at $11.52 per share on the same day, indicating a significant impact on investor value [3]. Legal and Investigation Context - Glancy Prongay & Murray LLP is leading the investigation on behalf of Tandem investors to explore possible claims for recovering losses incurred due to the stock price decline [1][4]. - The law firm has a strong track record in securities litigation, having recovered billions for investors and consistently ranked among the top firms in securities class action settlements [6][7].

LOS ANGELES, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Marex Group plc (“Marex” or the “Company”) (NASDAQ: MRX) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MAREX GROUP PLC (MRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On August 5, 2025, NINGI Research published a ...

Core Viewpoint - Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps that could endanger patients and impact investors [1][2]. Group 1: Company Issues - On August 7, 2025, Tandem disclosed a malfunction in some insulin pumps that could lead to a cessation of insulin delivery, potentially causing hyperglycemia and requiring medical intervention [2]. - The company notified affected customers between July 22 and 24, 2025, regarding the malfunction [2]. Group 2: Market Impact - Following the announcement of the malfunction, Tandem's stock price dropped by $2.87, or 19.9%, closing at $11.52 per share on August 7, 2025, resulting in financial harm to investors [3].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's revenue and growth potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the Class Period [2]. Group 2: Legal Process and Participation - Investors in Lantheus have until November 10, 2025, to seek appointment as lead plaintiff, representing the class in the litigation [3]. - A lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. - Participation as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Viewpoint - Investors in C3.ai, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's growth and the health of its CEO [1][2]. Summary by Sections Lawsuit Details - The lawsuit claims that from February 26, 2025, to August 8, 2025, C3.ai's management failed to disclose critical information, including that the company's optimistic growth reports were overly reliant on the CEO's health, which had not sufficiently improved [2]. - It is alleged that the positive statements made by the company regarding its business operations and future prospects were materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses on their C3.ai investments are encouraged to participate in the class action lawsuit, with a lead plaintiff deadline set for October 21, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating AVITA Medical, Inc. for potential violations of federal securities laws following significant financial issues related to unpaid claims for its Recell procedures [1][2]. Financial Performance - On August 7, 2025, AVITA Medical reported its second quarter 2025 financial results, indicating a six-month backlog in unpaid provider claims for Recell procedures, which negatively impacted first-half demand [2]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers and reduced utilization of Recell [2]. Stock Market Reaction - Following the announcement of the financial issues, AVITA's stock price dropped by $1.13, or 21%, closing at $4.25 per share on August 8, 2025, resulting in losses for investors [2].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating America's Car-Mart, Inc. for potential violations of federal securities laws following significant stock price declines related to financial disclosures and performance issues [1][2][3][4]. Group 1: Investigation Background - On July 15, 2025, Car-Mart announced a delay in filing its annual report due to the need for enhanced disclosures regarding loan modifications for financially distressed borrowers, resulting in a stock price drop of $3.12 (5.2%) to $57.26 [2]. - On July 30, 2025, Car-Mart revealed that certain previously issued financial statements were no longer reliable due to omissions in disclosures about loan modifications, causing the stock price to fall by $3.70 (7.5%) to $45.57 [3]. - On September 4, 2025, Car-Mart reported a 5.7% decline in sales volumes, attributing it to a focus on customer quality and vehicle performance, leading to a significant stock price drop of $8.14 (18.2%) to $36.51 [4].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were highly anticipated but yielded disappointing outcomes, raising concerns about the drug's regulatory approval and commercial viability [3]. Stock Market Impact - Following the announcement of the trial results, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025 [3].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Firefly Aerospace for possible violations of federal securities laws or other unlawful business practices [1][3]. Financial Performance - On August 7, 2025, Firefly offered 19,296,000 shares at a public offering price of $45.00 per share [3]. - Firefly reported revenue of $15.5 million for its initial quarterly results, reflecting a year-over-year decline of over 27% [3]. - The company reported total operating expenses of $58.3 million, which is a year-over-year increase of more than 12% [3]. - Following the financial report, Firefly's share price dropped by $7.58, or approximately 15.31%, from $49.52 on September 22, 2025, to close at $41.94 on September 23, 2025 [3].